Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 20/07/18 at 11:24am

As Brexit negotions have hit a stalemate this week, the United Kingdom's exit from the European Union has hit the headlines. While AstraZeneca have increased their stockpiles in preperation for a no-deal Brexit, the British parliament offered assurance that the UK would retain close ties with the EMA.

Atopic dermatitis commonly known as eczema, has come up twice this week as both Novartis and GSK settled deals on dermatology drugs. Equally big figures have been a theme as market intelligence firm Prohibition Partners has projected the European cannabis market will be worth more than €115 billion, while J&J was ordered to pay a record $4.68 billion in damages.

Check out the week's ten most popular articles on Pharmafile.com now!

10. J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy of its SGLT2 inhibitor Invokana (canagliflozin), but not because it had proved ineffective.

9. European cannabis market set to be worth €115.7 billion by 2028

The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the market intelligence firm Prohibition Partners.

8. FDA expands Pfizer and Astellas' Xtandi into castration-resistant prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand its label indications to include the treatment of metastatic castration-resistant prostate cancer (CRPC).

7. Senate claims Novartis misled public on Trump lawyer deal

A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen “was longer and more detailed than previously disclosed by the company” and that Novartis “explicitly sought to hire Michael Cohen to provide the company ‘access to key policymakers’ in the Trump administration.”

6. J&J ordered to pay $4.68 billion to talc-powder plaintiffs

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women who claimed that the multinational’s talc-based products had caused them to develop ovarian cancer.

5. Novartis buys eczema drug in €95m deal

Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and the German biotech company MorphoSys.

4. AstraZeneca increases drug stockpile in preparation for no-deal Brexit

The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the European Union in preparation for a hard, no-deal Brexit.

3. GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ subsidiary Dermavent Sciences, in a deal worth up to £250 million.

2. Renowned cancer researcher leaves ICR over bullying allegations

Leading geneticist and cancer researcher, Nazneen Rahman CBE, has resigned from her position as head of Genetics and Epidemiology at the London-based Institute of Cancer Research, following multiple allegations of bullying dating back 12 years

1. MPs vote to stay in EMA after Brexit

British MPs have voted for the UKs continued participation in the regulatory network operated by the European Medicines Agency (EMA) after Brexit.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches